ExpressPoints
Beyond BRCA: Exploring PARP Combinations in Prostate Cancer

Download this brief summary slideset from a live Webinar to review the rationale for and most recent clinical data on PARP inhibitor combination therapy in metastatic CRPC.
Charles J. Ryan, MD
Neal D. Shore, MD, FACS
Format: Microsoft PowerPoint (.ppt)
File Size: 891 KB
Released: March 3, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
AstraZeneca
Merck Sharp & Dohme Corp.
Pfizer

Related Content

In this slideset from Clinical Care Options (CCO), experts provide insights on clinical trials of PARP inhibitor combinations in prostate cancer

Karim Fizazi, MD, PhD Joaquin Mateo, MD, PhD Released: April 19, 2021

In this slideset from Clinical Care Options (CCO), experts present the rationale for PARP inhibitor combination therapies in prostate cancer

Karim Fizazi, MD, PhD Joaquin Mateo, MD, PhD Released: April 16, 2021

Downloadable slideset reviewing the latest evidence on PARP inhibitor combinations in prostate cancer, from Clinical Care Options (CCO)

Charles J. Ryan, MD Released: April 12, 2021

Charles J. Ryan, MD, reviews PARP inhibitor combination therapy clinical trials in prostate cancer and the evidence supporting these approaches from Clinical Care Options (CCO)

Charles J. Ryan, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: April 12, 2021 Expired: April 11, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue